Synthetic peptides are peptides produced through a manufacturing process rather than simply isolated from a biological sample. Describing a peptide as synthetic tells you about its origin; it does not, by itself, tell you its purity, amount, biological activity or suitability for a particular use.
Why are peptides synthesised?
Making a defined sequence allows researchers to investigate particular molecular questions. Modern synthesis can also support comparisons between many related sequences. For example, a 2024 primary methods study described parallel solid-phase synthesis in 384-well plates, illustrating how synthesis can serve systematic screening rather than a single finished medicine. (Schüttel et al., 2024)
The research question remains crucial. A material may be useful for testing an idea without having been evaluated as a clinical product. Manufacturing it successfully and demonstrating a treatment benefit are separate achievements.
Does synthetic mean different from a naturally occurring peptide?
It can be made to reproduce a specified sequence or to introduce a defined modification. The useful comparison is the actual molecular structure, not the marketing category. Names, abbreviations and descriptions should be checked against the specification rather than treated as complete identities.
A modification can be the central feature of an experiment. In the original Long Arg3 IGF-I work, for example, researchers compared deliberately altered analogues and examined their behaviour in different cell systems. (Francis et al., 1992) That is why “similar to” is not the same as “identical to”.
Four questions for any specification
| Property | Question to answer |
|---|---|
| Identity | What exact sequence, modification and chemical form is present? |
| Purity | What does the reported analytical percentage measure, under which method? |
| Content | How much of the named substance was measured in the sample? |
| Activity | What response occurred in a defined biological assay? |
Why purity and amount should not be confused
A percentage and a mass are different kinds of measurement. Before comparing them, read the report’s definitions and units. Do not assume that a headline percentage answers how many milligrams of the named substance are present.
A useful comparison sheet therefore gives purity and measured content separate columns. Retain the units, method description and sample identifier alongside each result. If one field is missing, record the gap instead of filling it with an assumption drawn from the other field.
Can a laboratory report establish clinical suitability?
A report can support the particular measurements it contains. It cannot answer questions that were not tested. Chemistry, microbial testing, stability, clinical benefit and regulatory status involve different evidence. The TGA separately assesses the quality, safety and effectiveness of therapeutic goods. (TGA, n.d.-b) Treat a laboratory report as a document with a defined scope, not a universal certificate.
This approach also makes missing information easier to describe. Write “not reported in the document reviewed” rather than assuming either a pass or a failure. A clear unknown is more useful than an invented assurance.
A practical research record
Record the full material name, sequence or identifier, batch, report identifier, test date, methods and units. Add the intended experimental use and any unresolved discrepancy. Keep the original report with the record so that another person can reproduce the interpretation.
Does synthetic mean unsafe—or safe?
Neither conclusion follows from the word alone. Suitability must be assessed for the actual material and use. A well-written specification states what is known, how it was established and what still needs evaluation.
That is the useful purpose of documentation: to make the next decision traceable, rather than to turn several different scientific questions into one attractive percentage.
References
Linked author–year citations identify the source for the nearby statement. Publication years refer to the journal issue where available; earlier online dates are noted below. “n.d.” means no publication date is displayed; letter suffixes distinguish sources by the same organisation. Tables labelled as editorial interpretation are our reading of the cited evidence.
- Francis, GL; Ross, M; Ballard, FJ; Milner, SJ; Senn, C; McNeil, KA; et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of molecular endocrinology, 8(3), 213-23. doi:10.1677/jme.0.0080213. PMID: 1378742.
- Schüttel, M; Will, E; Sangouard, G; Zarda, A; Habeshian, S; Nielsen, AL; et al. (2024). Solid-phase peptide synthesis in 384-well plates. Journal of peptide science : an official publication of the European Peptide Society, 30(4), e3555. doi:10.1002/psc.3555. PMID: 38220145.
- Therapeutic Goods Administration (n.d.-b). How we regulate therapeutic peptide products. No publication date displayed. Accessed 21 October 2026.